Aerovate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Jade Biosciences

16/08/2021 14:15

* Aerovate Therapeutics Inc  AVTE.OQ  reported a quarterly
adjusted loss of $23.80​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 16 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Aerovate Therapeutics Inc's reported EPS for the quarter was a
loss of $23.80​.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Aerovate Therapeutics Inc shares had fallen by 45.2% this
quarter.
* The company reported a quarterly loss of $5.78 million.
* Wall Street's median 12-month price target for Aerovate
Therapeutics Inc is $23.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated August 16 at 01:15 p.m.  ​All
figures in US dollars unless otherwise stated